Zymeworks’ HER2 Antibody Hits Target In Pivotal Biliary Tract Cancer Trial

First-In-Class Potential In Disease

3D Animation of antibodies
Zanidatamab Is A Bispecific Antibody That Targets HER2 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D